company background image
L8S logo

Grace Therapeutics DB:L8S Stock Report

Last Price

€2.78

Market Cap

€37.1m

7D

0%

1Y

40.4%

Updated

22 Dec, 2024

Data

Company Financials +

L8S Stock Overview

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. More details

L8S fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Grace Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Grace Therapeutics
Historical stock prices
Current Share PriceUS$2.78
52 Week HighUS$3.14
52 Week LowUS$1.89
Beta1.48
1 Month Change0%
3 Month Change17.80%
1 Year Change40.40%
3 Year Change-64.90%
5 Year Change-97.41%
Change since IPO-99.25%

Recent News & Updates

Recent updates

Shareholder Returns

L8SDE PharmaceuticalsDE Market
7D0%-2.2%-2.0%
1Y40.4%-15.6%6.9%

Return vs Industry: L8S exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: L8S exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is L8S's price volatile compared to industry and market?
L8S volatility
L8S Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: L8S's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine L8S's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aPrashant Kohliwww.gracetx.com

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

Grace Therapeutics, Inc. Fundamentals Summary

How do Grace Therapeutics's earnings and revenue compare to its market cap?
L8S fundamental statistics
Market cap€37.12m
Earnings (TTM)-€11.12m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
L8S income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$11.61m
Earnings-US$11.61m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did L8S perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:45
End of Day Share Price 2024/10/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Grace Therapeutics, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeByron Capital Markets